Document is current
Any future updates will be listed below
-
Authors
Porav, Sebastian A. https://orcid.org/0000-0003-4238-0083
Ptakova, Alexandra https://orcid.org/0009-0000-3057-3289
Bauer, Claudia C. https://orcid.org/0000-0003-4278-4803
Hammond, Kasia L. R. https://orcid.org/0000-0003-1333-482X
Beech, David J. https://orcid.org/0000-0002-7683-9422
Vlachova, Viktorie https://orcid.org/0000-0002-8621-0935
Muench, Stephen P. https://orcid.org/0000-0001-6869-4414
Bon, Robin S. https://orcid.org/0000-0003-1733-3680
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/P020208/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/Z514925/1)
British Heart Foundation (PhD studentship)
Royal Society (WL150028)
Wellcome Trust (108466/Z/15/Z)
Wellcome Trust (221524/Z/20/Z)
Wellcome Trust (218785/Z/19/Z)
Grantová Agentura České Republiky (GACR 24-10147S)
- License Information
-
More Information
Article History
Received: 26 June 2025
Accepted: 31 March 2026
First Online: 29 April 2026
Competing interests
: R.S.B. and D.J.B. are scientific co-founders and partners of the pharmaceutical start-up company CalTIC GmbH. R.S.B., D.J.B. and S.A.P. have received funding from CalTIC GmbH. D.J.B. is an inventor on the following patent applications: (1) PCT/GB2018/050369. TRPC ion channel inhibitors for use in therapy. Filing date: 9th February 2018; (2) 62/529,063. Englerin derivatives for the treatment of cancer. Filing date: 6th July 2017. The other authors declare no competing interests.
